18-Fluorodeoxyglucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma
- PMID: 23353642
- DOI: 10.1016/j.cgh.2012.12.033
18-Fluorodeoxyglucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma
Abstract
Background & aims: There are no accurate and reliable tools for diagnosis of early stage pancreatic ductal adenocarcinoma (PDA) or small metastatic lesions. It is also a challenge to differentiate PDA from focal mass-forming pancreatitis (FMP). There is controversy regarding the efficacy of 18-fluorodeoxyglucose positron-emission tomography (FDG-PET) in the diagnosis of PDA. We investigated whether FDG-PET provides information that, combined with data from other imaging techniques, can aid in decision making for patients with suspected PDA.
Methods: We performed a retrospective analysis of data collected from 232 consecutive patients with suspected PDA at Kobe University Hospital from January 2006 through June 2012. All patients underwent a diagnostic imaging protocol that included multidetector row computed tomography, superparamagnetic iron oxide-enhanced magnetic resonance imaging, and FDG-PET. Based on endoscopic ultrasonography, fine-needle aspiration biopsy, or endoscopic retrograde cholangiopancreatography analyses, 218 patients had PDA (89 underwent resection and 129 did not) and 14 patients had FMP (8 had focal mass-forming chronic pancreatitis and 6 had focal mass-forming autoimmune pancreatitis).
Results: FDG-PET detected 50% of stages 0 and I, 91.9% of stage II, 100% of stage III, and 96.8% of stage IV tumors. Detection was affected significantly by tumor size (P = .024) and T stage (P = .023) in resected tumors. Multidetector row computed tomography detected significantly more liver metastases than FDG-PET. Few para-aortic lymph node or peritoneal metastases were detected by FDG-PET. FDG-PET correctly identified 11 of the 14 patients with FMP (5 of 8 with focal mass-forming chronic pancreatitis and 6 of 6 with focal mass-forming autoimmune pancreatitis).
Conclusions: FDG-PET is not effective in detecting early stage PDA and small metastases, or in differentiating PDA from FMP. Combining FDG-PET with current diagnostic techniques for PDA did not provide any decisive information, therefore it should not be included in this analysis.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.Ann Surg. 2009 Dec;250(6):957-63. doi: 10.1097/SLA.0b013e3181b2fafa. Ann Surg. 2009. PMID: 19687736
-
18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.Ann Surg. 2007 Dec;246(6):932-7; discussion 937-9. doi: 10.1097/SLA.0b013e31815c2a29. Ann Surg. 2007. PMID: 18043094
-
Comparison of F-18-FDG PET/CT findings between pancreatic solid pseudopapillary tumor and pancreatic ductal adenocarcinoma.Eur J Radiol. 2014 Jan;83(1):231-5. doi: 10.1016/j.ejrad.2013.09.031. Epub 2013 Nov 14. Eur J Radiol. 2014. PMID: 24290142
-
Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment.J Hepatobiliary Pancreat Surg. 2004;11(1):4-10. doi: 10.1007/s00534-002-0775-x. J Hepatobiliary Pancreat Surg. 2004. PMID: 15747028 Review.
-
[The value of fluorodeoxyglucose positron emission tomography (FDG-PET) in differentiation of pancreatic lesions].Zentralbl Chir. 2003 May;128(5):375-8. doi: 10.1055/s-2003-40030. Zentralbl Chir. 2003. PMID: 12813634 Review. German.
Cited by
-
Surveillance for neoplasia in the pancreas.Best Pract Res Clin Gastroenterol. 2016 Dec;30(6):971-986. doi: 10.1016/j.bpg.2016.10.013. Epub 2016 Nov 5. Best Pract Res Clin Gastroenterol. 2016. PMID: 27938791 Free PMC article. Review.
-
Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: 18 F-labeled rBC2LCN lectin.Cancer Sci. 2023 Aug;114(8):3364-3373. doi: 10.1111/cas.15846. Epub 2023 May 19. Cancer Sci. 2023. PMID: 37203465 Free PMC article.
-
The role of endoscopic ultrasound in the detection of pancreatic lesions in high-risk individuals.Fam Cancer. 2024 Aug;23(3):279-293. doi: 10.1007/s10689-024-00380-5. Epub 2024 Apr 4. Fam Cancer. 2024. PMID: 38573399 Free PMC article. Review.
-
A prospective study of the impact of fluorodeoxyglucose positron emission tomography with concurrent non-contrast CT scanning on the management of operable pancreatic and peri-ampullary cancers.HPB (Oxford). 2015 Jul;17(7):624-31. doi: 10.1111/hpb.12418. Epub 2015 Apr 30. HPB (Oxford). 2015. PMID: 25929273 Free PMC article.
-
Regional lymph node metastasis detected on preoperative CT and/or FDG-PET may predict early recurrence of pancreatic adenocarcinoma after curative resection.Sci Rep. 2022 Oct 14;12(1):17296. doi: 10.1038/s41598-022-22126-y. Sci Rep. 2022. PMID: 36241906 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical